NCT02129036已完成不适用
Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5
- 主要终点
- Overall survival (OS)
研究概览
简要总结
Clear cell carcinoma comprises 5-10% of surface epithelial ovarian cancers, and about 30-40% of the patients with clear cell carcinoma are diagnosed in the advanced stage. The investigators studied the response to chemotherapy and survival for either paclitaxel-platinum based chemotherapy or conventional platinum-based chemotherapy among all stages clear cell ovarian carcinoma. Prognostic factors for survival among the patients with pure, advanced, clear cell ovarian carcinoma were also evaluated.
详细描述
- Several authors have reported frequent admixtures of clear cell ovarian carcinoma with serous, mucinous, and endometrioid tumors. However, few papers addressed the difference in response to chemotherapy and survival between patients with pure and mixed-type advanced clear cell carcinoma.
- Recent trends in the clinical management of advanced ovarian cancer include increased attention to maximal cytoreduction and general acceptance of paclitaxel-platinum-based adjuvant chemotherapy.
- The introduction of paclitaxel markedly changed the postoperative management of ovarian cancer patients, but the results and value of these newer efforts and therapies applied to clear cell carcinoma are as yet undetermined.
- Today, paclitaxel-platinum-based chemotherapy is becoming the standard regimen for ovarian cancer worldwide. Previous research suggests a potential benefit of paclitaxel plus carboplatin regimens for stage I clear cell carcinoma. However, few papers specifically addressed the efficacy of paclitaxel-platinum-based chemotherapy for advanced clear cell carcinoma because clear cell carcinoma occurs only rarely in Western countries.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of Ovarian clear cell carcinoma
排除标准
- •not undergo operation
结局指标
主要结局
Overall survival (OS)
时间窗: Overall survival (up to 6 years)
次要结局
未报告次要终点
研究者
Chih-Ming Ho
Dr
Cathay General Hospital
相似试验
招募中
不适用
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in SwitzerlandHereditary Breast and Ovarian CancerLynch SyndromeNCT03124212University of Basel700
已完成
不适用
Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4Ovarian CancerOvarian TumorNCT02326064Centre Hospitalier Departemental Vendee221
招募中
不适用
A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omicsOvarian CancerNCT05251883Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University200
Unknown
不适用
The Development of Human Immunologic Assays Specific to Folate Receptor AntigenOvarian CancerNCT00155935National Taiwan University Hospital50
招募中
不适用
SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTSOvarian CancerNCT06071286Fondazione Policlinico Universitario Agostino Gemelli IRCCS30